The EBiSC team is working hard to implement improvements in how EBiSC operates.
Due to some short-term disruption, please get in touch via
Contact@EBiSC.org if
the cells you would like to access are currently listed as unavailable or you
are ordering from outside of Europe.
BIONi010-C-17
BIONi010-C TREM2 KO
Gene-edited iPSC line
We are currently making some changes to how EBiSC operates and because
of this there is a short period of time where orders cannot be placed.
If you are interested in accessing these cells, please contact EBiSC directly. For more information about the current transition process see here.
If you are interested in accessing these cells, please contact EBiSC directly. For more information about the current transition process see here.
A CLIP contains information about a cell line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the cell line.
The EBiSC Access and Use Agreement must be completed along with an individual
Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org
for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
hPSCreg name | BIONi010-C-17 |
Alternative name(s) |
BIONi010-C TREM2 KO
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
BIONi010-C-25 (BIONi010-C heterozygous TREM2 KO) BIONi010-C-7 (BIONi010-C Trem2 R47H) BIONi010-C-8 (BIONi010-C Trem2 T66M, #Y5-80) BIONi010-C (BIONi010-C, K3P53) BIONi010-C-2 (BIONi010-C ApoE E3/E3 #H8 P32) BIONi010-C-3 (BIONi010-C ApoE KO #KO30 P30) BIONi010-C-4 (BIONi010-C ApoE E4/E4 #B44 P27) BIONi010-C-5 (BIONi010-C CD33 E2del #N14 P26) BIONi010-C-6 (BIONi010-C ApoE E2/E2) BIONi010-C-9 (BIONi010-C CD33 KO) BIONi010-C-13 (BIONi010-C + NGN2 #I7-26) BIONi010-C-15 (BIONi010-C +dox inducible NGN2-GFP) BIONi010-C-70 (BIONi010-C with an APOE 2/2 genotype with an additional, homozygous christchurch mutation) BIONi010-C-71 (BIONi010-C with an APOE 3/3 genotype with an additional, homozygous christchurch mutation) BIONi010-A (K1P53) BIONi010-B (K2P53, BIONi010-B) BIONi010-C-18 (BIONi010-C TBK1 KO) BIONi010-C-51 (BIONi010-C TNNI3-mCherry reporter) BIONi010-C-19 (BIONi010-C IKBKE KO) BIONi010-C-10 (HNF1AP291fsinsC +/- 54-5) BIONi010-C-11 (HNF1AP291fsinsC -/- 66-1) BIONi010-C-12 (HNF4ApR309C -/- 2-4) BIONi010-C-52 (BIONi010-C with an APOE 2/2 genotype (with two functional alleles in contrast to BIONi010-C-6)) BIONi010-C-53 (BIONi010-C with an APOE 3/3 genotype (with two functional alleles in contrast to BIONi010-C-2)) BIONi010-C-55 (BIONi010-C TNNI3-mCherry/TNNI1-EGFP dual reporter cl. 74) BIONi010-C-24 (BIONi010-C Dox a-syn) |
Notes | No larger chromosomal aberrations to be reported. Chr22: 1,4Mbp duplication in q11.23 |
Provider |
|
Depositor | Bioneer (BION) |
Owner | Bioneer (BION) |
Distributors |
EBiSC
|
Derivation country | Denmark |
External Databases |
|
hPSCreg | BIONi010-C-17 |
BioSamples | SAMEA104386270 |
Cellosaurus | CVCL_RM88 |
Wikidata | Q54796761 |
General Information |
|
Publications | View all related publications on hPSCreg (5) |
This EBiSC line can be used for: |
Yes
Research use: allowed
Clinical use: no
Commercial use: no
|
Subclone of | (not in EBiSC, see BIONi010-C in hPSCreg) |
Donor Information#
General Donor Information |
|
Sex | male |
Ethnicity | Black or African-American |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
Other cell lines of this donor | |
External Databases (Donor) |
|
BioSamples | SAMEA3105780 |
hIPSC Derivation#
General |
|
More source cell information can be found in the parental cell line
BIONi010-C in hPSCreg.
|
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Episomal |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions#
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
EDTA
|
O2 Concentration | 20 % |
CO2 Concentration | 5 % |
Medium |
Essential 8™
|
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation#
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
SOX2 |
Yes |
|
||||
POU5F1 (OCT-4) |
Yes |
|
||||
SSEA-3 |
Yes |
|
||||
SSEA-4 |
Yes |
|
||||
SSEA-1 |
No |
|
Score:
Marker | Present | Absent |
mCpG | ||
OCT4 |
Morphology pictures
TREM2 KO cl. 24-54 D1 thaw after banking.tif
Phase contrast image 1 day after thawing
Method documentation
06-Sep-2017-Layout.tiff
Flow Cytometry with pluripotency markers
qPCR BIONi010-C-17.tif
qPCR with pluripotency markers
Differentiation Potency
In vitro directed differentiation
Morphology
Protocol or reference
BIONi010-C-17 endo D5.tif
Flow cytometry of in vitro differentiation to endoderm
In vitro directed differentiation
Morphology
Protocol or reference
BIONi010-C-17 meso D5.tif
Flow cytometry of in vitro differentiation to mesoderm
In vitro directed differentiation
Morphology
Protocol or reference
BIONi010-C-17 ecto D5.tif
Flow cytometry of in vitro differentiation to ectoderm
Microbiology / Virus Screening |
|
HIV 1 | Negative |
HIV 2 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Mycoplasma | Negative |
Sterility |
|
Inoculation for microbiological growth | No Contaminants Detected |
Mycoplasma | Not Detected |
Viability | Viable post-cryopreservation |
Genotyping#
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
Genetic Modification#
Disease/phenotype related modifications |
|